Dynavax Technologies (DVAX) Stock Price, News & Analysis

Company Overview

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases. The company’s approach centers on pairing antigen constructs with adjuvant technologies designed to improve efficacy, durability and overall immunogenicity. In parallel, Dynavax is exploring immuno-oncology applications by investigating how its TLR agonists can synergize with checkpoint inhibitors and other cancer therapies.

Dynavax maintains a presence in North America and Europe, both through direct commercialization efforts and strategic partnerships. In addition to its Emeryville headquarters, the company operates research and development facilities in the United Kingdom and collaborates with global pharmaceutical firms to broaden the reach of its vaccine and adjuvant technologies. These alliances have enabled Dynavax to navigate regulatory requirements and facilitate supply chain distribution in multiple regions.

Under the leadership of President and Chief Executive Officer Tony Wood, who joined the company in 2017, Dynavax continues to advance its development programs and expand commercial opportunities. The company’s scientific team includes experts in immunology, infectious disease and vaccine manufacturing, supporting a disciplined approach to clinical research and regulatory strategy. As Dynavax progresses its pipeline through clinical milestones, it aims to address unmet medical needs in both prophylactic and therapeutic settings.

Key Stats

• Today's Range: $9.20 to $9.44
• 50-Day Range: $9.41 to $11.36
• 52-Week Range: $9.20 to $14.63
• Volume: 1.82 million shs
• Average Volume: 2.07 million shs
• Market Capitalization: $1.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.33
• Consensus Rating: Moderate Buy

Dynavax Technologies Stock Analysis - MarketRank™

Dynavax Technologies scored higher than 89% of companies evaluated by MarketBeat, and ranked 125th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Dynavax Technologies has a consensus price target of $24.33, representing about 161.8% upside from its current price of $9.29.

Amount of Analyst Coverage

Dynavax Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 53.13%

Earnings Growth

Earnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dynavax Technologies is -20.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dynavax Technologies is -20.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dynavax Technologies has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.39% of the float of Dynavax Technologies has been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Dynavax Technologies has recently increased by 1.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dynavax Technologies does not currently pay a dividend.

Dividend Growth

Dynavax Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.59

Percentage of Shares Shorted

12.39% of the float of Dynavax Technologies has been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Dynavax Technologies has recently increased by 1.66%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.62

News Sentiment

Dynavax Technologies has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Dynavax Technologies this week, compared to 6 articles on an average week.

MarketBeat Follows

1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Dynavax Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $41,116.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.98% of the stock of Dynavax Technologies is held by insiders.

Percentage Held by Institutions

96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DVAX Stock Analysis - Frequently Asked Questions

How have DVAX shares performed this year?

Dynavax Technologies' stock was trading at $12.77 at the beginning of the year. Since then, DVAX shares have decreased by 27.2% and is now trading at $9.2930.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Corporation (NASDAQ:DVAX) released its quarterly earnings results on Thursday, August, 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. The biopharmaceutical company earned $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive trailing twelve-month return on equity of 5.10%.
Read the conference call transcript.

Who are Dynavax Technologies' major shareholders?

Top institutional shareholders of Dynavax Technologies include State Street Corp (5.45%), Chicago Capital LLC (4.35%), Geode Capital Management LLC (2.24%) and Blair William & Co. IL (1.90%). Insiders that own company stock include Andrew A F Hack, Robert Janssen, Francis Cano, Scott Dunseth Myers, David F Novack and Justin Burgess.
View institutional ownership trends.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DVAX
• CIK: 1029142
• Web: www.dynavax.com
• Phone: (510) 848-5100
• Fax: 510-848-1327
• Employees: 350
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Dynavax Technologies: $24.33
• High Price Target: $32.00
• Low Price Target: $10.00
• Potential Upside/Downside: +158.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 29.41
• P/E Growth: N/A
• Net Income: $27.31 million
• Net Margins: -16.67%
• Pretax Margin: -15.56%
• Return on Equity: 5.10%
• Return on Assets: 3.00%

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 6.65
• Quick Ratio: 6.01

Sales & Book Value

• Annual Sales: $316.27 million
• Price / Sales: 3.49
• Cash Flow: $0.16 per share
• Price / Cash Flow: 59.42
• Book Value: $4.54 per share
• Price / Book: 2.07

Miscellaneous

• Outstanding Shares: 117,267,000
• Free Float: 113,772,000
• Market Cap: $1.10 billion
• Optionable: Optionable
• Beta: 1.24